Fluicell Ab · OMXSTO:FLUI
Fluicell Ab — Investor Day (May 2023)
70 slides from Fluicell Ab's investor day presentation, May 22, 2023
Slide 1: Fluicell Capital Markets Day
FLUICELL Capital Markets Day May 22, 2023
Slide 2: Disclaimer
Disclaimer This document has been prepared in good faith, but the information contained within has not been subject to a verification exercise. No representation or warranty, express or implied, is given by or on behalf of the Company, its group companies or any of their respective shareholders, dir
Slide 3: Victoire Viannay, CEO
Victoire Viannay CEO FLUICELL Fluicell Capital Markets Day 2023 3
Slide 4: Transforming medicine – one cell at a time
Transforming medicine – one cell at a time Bringing the power of precision technology to the center of drug development, and releasing the potential of regenerative medicine Fluicell Capital Markets Day 2023 4
Slide 5: Agenda
Agenda Introduction, Financial performance and Strategy Victoire Viannay Markets and trends Nelson Khoo Life science solutions Gavin Jeffries Regenerative medicine Tatsiana Lobovkina Tissue-based drug development models Gavin Jeffries Summary and takeaways Victoire Viannay Q&A Session Fluicell Capit
Slide 6: Fluicell Targets Key Future Healthcare challenges
Fluicell Targets Key Future Healthcare challenges • Tissue-related diseases lacking adequate care options cause more than 20 million deaths every year. • 90 % of all drug candidates fail to pass clinical trials. • Major contributing factor to human suffering and increasing healthcare and pharmaceuti
Slide 7: Fluicell's 3T response to healthcare challenges
Fluicell’s 3T response to healthcare challenges: Technology, Tissue-based models and Therapeutics Research technology Therapeutic products Tissue-based models • Five platform products on the • Human tissue-based transplants • Human tissue-based disease market targeting biological and for regenerativ
Slide 8: The history of Fluicell
The history of Fluicell Fluicell Capital Markets Day 2023 8
Slide 9: Fluicell in numbers
Fluicell in numbers 20 5 3 Employees Platform Business Areas products 18 22 60+ Countries Patents Installed Instruments Fluicell Capital Markets Day 2023 9
Slide 10: Improved financial performance
Improved financial performance • Continuous revenue growth after 2021. • Approaching goal of 100 % annual revenue growth. • 113 % organic sales growth in Q1 2023. • Strong gross margin. Fluicell Capital Markets Day 2023 10
Slide 11: Fluicell's strategic goals
• Mature as life science company through organic growth. Fluicell’s • Cultivate position as technology leader strategic within 3D bioprinting. goals • Establish Fluicell’s bioprinted human tissues as primary choice as research model for pharmaceutical development and medical research. • Obtain a pos
Slide 12: Focus Research technology
• Current main source of revenue. Focus • New products and services to capture growing market for precision Research research tools. technology • Increase revenue through complete solution packages and customer brand loyalty through expanded after-sales services. • Strengthened market position as mi
Slide 13: Focus Tissue-based disease models
• Fluicell’s bioprinted tissues improve Focus on current standards for in vitro drug testing. Tissue-based • Add value to drug development disease models through improved predictive power and reduced costs. • Target increasing demand for non- animal research models • Strengthen IP to create opportun
Slide 14: Focus Regenerative medicine
• ATMP new paradigm in medicine • National strategic area for healthcare Focus innovation with many collaboration opportunities Regenerative • Recent partnership and acquisition medicine agreements show increasing investments from major pharma • Type 1 diabetes focus area with advancements towards i
Slide 15: Focus TO4
• Opportunity to support Fluicell’s expansion in our three business areas. Focus • How fast we are able to reach our goals depends on investor support. TO4 • Establish long-term relationship with strong investors. • Fully supported by board and senior management. • Together we are stronger, and thro
Slide 16: Goal highlights 2022-2024
Goal highlights 2022-2024 Technology development Human in vitro disease models • Product integration and offering expansion • Agreement with Roche to develop models • Research grants or collaborations for for cardiovascular safety screening product & application development • EU grant to develop hum
Slide 17: Thank you!
Thank you! Fluicell Capital Markets Day 2023 17
Slide 18: Fluicell's markets and trends
Fluicell’s markets and trends Nelson Khoo CHIEF BUSINESS DEVELOPMENT AND SALES OFFICER Fluicell Capital Markets Day 2023 18
Slide 19: Trends & Market Drivers
Trends & Market Drivers Trends Drivers • Aging population • Chronic diseases without adequate treatment options, e.g. Diabetes / Obesity, • Personalized medicine Liver disease, Neurological Diseases • Increased drug development and Cardiovascular disease healthcare costs • Precision medicine develop
Slide 20: Working with the brightest minds
Working with the brightest minds Fluicell Capital Markets Day 2023 20
Slide 21: Innovative products targeting growth markets
Innovative products targeting growth markets, Leveraging strong synergies to area commonalities Research Therapeutic Biorelevant solutions products human models TAM USD 7 B TAM USD 20 B TAM USD 30 B CAGR 15% (2030) CAGR >20% (2028) CAGR >10% (2030) • Sales of instruments, • Long-term focus on partne
Slide 22: Sales trends supported by major sector drivers
Sales trends supported Need better human proxy of effects of any drug or biologics. * human on a chip by major sector drivers Universities, institutes and research funders TOXICITY PLATFORM are driving advance in cell and gene Need to create intricate patterns therapeutics mimicking complex human ti
Slide 23: 3D bioprinting market
3D bioprinting market Market value USD 5.3 B 2030 CAGR 12.5 % Fluicell’s role on the market Fluicell is a market challenger and innovation leader, offering unique capabilities that addresses expressed needs in core customer base and targets lack among important competing technologies. • 50.7 % of th
Slide 24: The drug development challenge
2022 2021 11,35 Pre-Clinical 10,22 2,95 Phase 1 2,68 2,92 Phase 2 2,75 1,12 The drug development challenge Phase 3 1,03 $2+ billion to bring a drug into place with 10-year avg timeline 2,31 Pre-Registration 2,67 Adding the ability to see the safety profile early 1,7 Registered can derisk the entire
Slide 25: Drug Safety Profiling Toxicity
Drug Safety Profiling Toxicity Lack of relevant safety and efficacy are the principal causes of the failure of the drugs, which become evident only in Phases II and III of clinical trials. With mature 3D bioprinting, drug developers can address the complications associated with human clinical trials
Slide 26: Cardiac toxicity market
Cardiac toxicity market Driver is the need for better replica of disease models by printed 3D tissue structures or organoids. $18.3B $34.8B 2022 2030 In 2022, 35% of revenue is 6.4B for hERG assay. A predicate for 3D tissues when such a model is validated 36.1% 35.1% Market share, hERG assay market
Slide 27: Regenerative medicine market
Regenerative medicine market Market value USD 60.3B 2027 CAGR 23.2 % Target market for Fluicell’s research solutions and long-term therapeutic development Type 1 diabetes therapeutic market value $24B (2029, CAGR 17.5 %) Recent deals between pharma and biotech companies demonstrate growing interest
Slide 28: Thank you!
Thank you! Fluicell Capital Markets Day 2023 28
Slide 29: Fluicell's life science solutions
Fluicell’s life science solutions Gavin Jeffries CTO FLUICELL Fluicell Capital Markets Day 2023 29
Slide 30: Lab-on-a-Tip
LAB-ON-A-TIP Innovative research solutions for single- cell biology and precision bioprinting BioPen Dynaflow Resolve Biozone 6 Biopixlar Biopixlar AER Fluicell Capital Markets Day 2023 30
Slide 31: Delivering… Where, When, & What
Delivering… Where, When, & What …required Fluicell Capital Markets Day 2023 31
Slide 32: BioPen & Biozone 6
BioPen & Biozone 6 Microfluidic single-cell solution delivery Directly target individual cells Expose just one or a small number of cells Full user control of position and timing Repeatable protocols with automation options No risk of contamination Deliver reagents to only the target cells Low compo
Slide 33: BioPen
BioPen Microfluidic single-cell solution delivery – Versatility with precision • Study fast processes with sub-second exchange time • Useable in any biological research setting, from single cell to tissue experiments • Easy integration into almost any microscopy platform • Deliver multiple solutions
Slide 34: Biozone 6
Biozone 6 Single-cell solution delivery – Tailored for pharma work flows 6 solutions per device Perform dose-response assays on single-cell level or compare multiple compounds Repeatable protocols Repeatable protocols and low variability ensures reliable results Seamless solutions switching Dose res
Slide 35: Biopixlar & Biopixlar AER
Biopixlar & Biopixlar AER A leading bioprinting technology that can create tissues at superhigh resolution resembling human organs. Key driver for rapid entry into fast-growing regenerative medicine market Fluicell Capital Markets Day 2023 35 35
Slide 36: Biopixlar & Biopixlar AER
Biopixlar & Biopixlar AER • Custom patterning of biologically relevant tissues. • Build tissues in native cell media without any binding matrix. • Pattern multicell type structures, islets and spheroids. • Print patient material – ideal for personalized medicine. Fluicell Capital Markets Day 2023 36
Slide 37: Testimonial: Dr. Carlos Mota, Maastricht University
“ I believe that the capabilities of Biopixlar to precisely position single cells is a missing link in a bioprinting space as the cell-cell and cell-material interactions plays vital roles on the biological signaling necessary for tissue “ construct maturation and function. Dr. Carlos Mota Maastrich
Slide 38: Biopixlar
BIOPIXLAR Build tissues directly from your cells Hacat A431 Hacat Fluicell Capital Markets Day 2023 38
Slide 39: The Biopixlar Advantage
THE BIOPIXLAR ADVANTAGE Fluicell Capital Markets Day 2023 39
Slide 40: Precision tailored tissues
Precision tailored tissues: Communication, migration, invasion, response Complex tissues for Direct printing of spheroids, communication or invasion assays organoids and 3d cell culture Fluicell Capital Markets Day 2023 40
Slide 41: Biopixlar: Pushing the bounds of science together
“Fluicell’s technology is the first of its kind to enable single-cell resolution bioprinting, with precision, speed and reproducible BIOPIXLAR accuracy, in a manner never before possible. Pushing the This technology certainly provides a new bounds of science tool for tissue engineers and biologists
Slide 42: Thank you!
Thank you!
Slide 43: Regenerative medicine at Fluicell
Regenerative medicine at Fluicell Tatsiana Lobovkina CSO FLUICELL Fluicell Capital Markets Day 2023 43
Slide 44: The next level in ATMP development
The next level in ATMP development • Establishing leadership in a new niche of regenerative medicine through game-changing technology and innovation • Leveraging Biopixlar and Biopixlar AER high-precision bioprinting platforms to tailor and produce organ-restoring tissues • Targeting therapeutic are
Slide 45: Closing the loop on type 1 diabetes
Closing the loop on type 1 diabetes Treating type 1 diabetes with artificial islets Fluicell’s vision is to transform how we treat type 1 diabetes using bioprinted tissue therapeutics. Our goal is to provide patient-tailored artificial pancreatic islets for glycaemic control. Fluicell Capital Fluice
Slide 46: Closing the loop on type 1 diabetes
Closing the loop on type 1 diabetes Type 1 diabetes is a growing medical concern with a global annual cost burden of $90 billion. Existing insulin-based treatments fail to provide adequate care and T1D patient still experience significant impact on health and wellbeing. Cell therapies for beta cell
Slide 47: Type 1 diabetes, a growing concern
Type 1 diabetes, a growing concern $29 B 175 000 $90 B Annual savings in US Annual deaths due to T1D Annual cost globally from T1D cell therapy Increasing 3% per year 9M 15 M 38 % Children and People leaving of all new diagnosed adults with T1D with T1D in 2040 cases of T1D under the age of 20 47 Fl
Slide 48: Type 1 diabetes
Type 1 diabetes Type 1 diabetes (T1D) is a life-long autoimmune disease, in which the pancreas does not make insulin (or makes very little insulin). Fluicell Capital Markets Day 2023 48
Slide 49: Pancreatic Islets
Pancreatic Islets Small islands of cells producing hormones that regulate blood glucose levels Islet diameter is 50-150 μm 50–75% β-cells, insulin-secreting 25–35% α-cells, glucagon-secreting β-cells other cells Islets are vascularized and innervated α-cells In Type 1 diabetes, the insulin-producing
Slide 50: Artificial pancreatic cells
Artificial pancreatic cells Using Biopixlar, Fluicell’s goal is to develop artificial islets capable of replicating the glycostatic function of the pancreatic islets Existing treatments rely on insulin injections or donated pancreatic islets. Fluicell’s ability to engineer islets gives us a unique p
Slide 51: Engineering artificial islets
Engineering artificial islets Bioprinting microtissues directly from cell suspension enables cell level control over islet size, cell ratios, islet density, and microenvironment composition, all of which can be tailored to patient specific needs. The development target is to replicate unique codepen
Slide 52: Engineering artificial islets
Engineering artificial islets Bioprinting of AIs composed of α, β, and endothelial cells Fluicell Capital Fluicell Capital Markets Markets Day Day 2023 2023 52 52
Slide 53: Therapeutic concept: Hydrogel embedded artificial islets
Therapeutic concept: Hydrogel embedded artificial islets Hydrogel embedding provides protection from immune system and facilitates transfer from production to transplantation Fluicell Capital Markets Day 2023 53
Slide 54: Therapeutic concept: Hydrogel embedded artificial islets
Therapeutic concept: Hydrogel embedded artificial islets Hydrogel embedding provides protection from immune system and facilitates transfer from production to 4 mm transplantation Fluicell Capital Markets Day 2023 54
Slide 55: Glucose response
Glucose response Artificial islets are responsive to glucose stimulation by secreting elevated insulin. Beta cells directly after printing. Day 0 Day 7 Fluicell Capital Markets Day 2023 55
Slide 56: Key features for continued therapeutic development
Key features for continued therapeutic development • Contain key pancreatic cell types - alpha, beta and endothelial cells. • Equivalent in size to native pancreatic islets. • Responsive to glucose stimulation – up to 5-fold increase in insulin secretion. • Hydrogel layers provide protection. • Func
Slide 57: Thank you!
Thank you! Fluicell Capital Markets Day 2023 57
Slide 58: Tissue-based disease models
Tissue-based disease models Gavin Jeffries CTO FLUICELL Fluicell Capital Markets Day 2023 58
Slide 59: Why bioprinted disease models
Why bioprinted disease models Low relevance of existing models Costly drug Existing cell-based and animal models fail to development combine biological relevance and systemic It can take 12+ years to response. Tissue engineered model offers a develop a drug and 9 of 10 way to do both. candidates fai
Slide 60: Biopixlar-generated in vitro models
Biopixlar-generated in vitro models Biopixlar enables a jump directly to stage 4/5 Bioprinting roadmap shows stages of bioprinted tissue technology evolution. Fluicell Capital Markets Day 2023 60
Slide 61: Biopixlar-generated in vitro models
Biopixlar-generated in vitro models High-resolution tissue engineering The Biopixlar printing technology makes it possible to build bio-relevant models tailored to research and drug development needs, using any cell source. Suited for precision medicine Biopixlar is designed for handling small volum
Slide 62: Current mono-cultures fail to capture cardiac biology
Current mono-cultures fail to capture cardiac biology • Current State of the art is typically cardiomyocyte (CM) monoculture or simple mixtures (95% CM) • Cardiomyocytes account for 77% of heart volume and 33% of the cell number. CM monoculture is an incomplete representation of native tissue. • Mon
Slide 63: Need for advanced cardiac models
Need for advanced cardiac models Need to replicate complex microenvironment 1 and interplay between the cell types beyond simple mono culture iPSC-CM 2 Replicate role for each cell type in maintaining homeostasis and restoration of function upon acute damage or toxic exposure Establish a more refine
Slide 64: Fluicell's cardiac model development
Fluicell’s cardiac model development Repeatable model Cardiac safety Developing a repeatable model holds incredible workflow integration potential for establishing services and licences Pilot investigations in both of technology and tissue models collaboration into establishing advanced multi-cell t
Slide 65: Hoffmann-La Roche collaboration
Fluicell’s cardiac model development Hoffmann-La Roche collaboration Pilot study to investigate the compatibility of Fluicell’s bioprinting 1. approach to generate cardiac tissues as in vitro cardiac models, for safety pharmacology. Initiated 2020, completed 2022. Fluicell successfully delivered on
Slide 66: Markets directly targeted by Fluicell's cardiac tissue models
Markets directly targeted by Fluicell’s cardiac tissue models Cardiac toxicity screening Cardiac safety services $35 B 8.3 % $1 B 11.2 % 2030 CAGR 2022-2030 2027 CAGR 2022-2027 Fluicell Capital Markets Day 2023 66
Slide 67: Thank you!
Thank you! Fluicell Capital Markets Day 2023 67
Slide 68: Take-home message
TAKE-HOME MESSAGE We advance in our three business areas: research technologies, tissue-based disease models and regenerative medicine, and meet the goals that we communicated in the prospectus, published last year. These three areas represent rapidly growing markets where Fluicell has the ability t
Slide 69: Q&A
Q&A Fluicell Capital Markets Day 2023 69
Slide 70: Fluicell Capital Markets Day 2023
Fluicell Capital Markets Day 2023 70